We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+2.22%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$563M
AUM Growth
+$168M
Cap. Flow
+$106M
Cap. Flow %
18.87%
Top 10 Hldgs %
78.85%
Holding
47
New
15
Increased
6
Reduced
2
Closed
11
Avg Time Held Equity + Options
2.2 quarters
Top 10 Avg Time Held Equity + Options
2.4 quarters
Top 20 Avg Time Held Equity + Options
2.2 quarters
Avg Time Held Equity only
2.4 quarters
Top 10 Avg Time Held Equity only
2.6 quarters
Top 20 Avg Time Held Equity only
2.5 quarters

Top Buys

Rank Stock Value
1
KYNB icon
Kyntra Bio
KYNB
+$43M
2
FBRX icon
Forte Biosciences
FBRX
+$22.5M
3
SGMO icon
SANGAMO THERAPEUTICS INC
SGMO
+$16.5M
4
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$14.7M
5
EDIT icon
Editas Medicine
EDIT
+$12.9M

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$13.3M
2
ATRA icon
Atara Biotherapeutics
ATRA
+$8.94M
3
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$5.68M
4
XNCR icon
Xencor
XNCR
+$5.62M
5
KURA icon
Kura Oncology
KURA
+$5.26M

Sector Composition

Rank Sector Weight
1 Healthcare 76.97%
2 Miscellaneous 23.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
DRNA
26
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.44M 0.43%
767,992
+385,992
+101% +$1.22M
2017 Q1
1 quarter
ADVM icon
27
DELISTED
Adverum Biotechnologies
ADVM
$2.19M 0.39%
87,445
– –
2016 Q3
3 quarters
NERV icon
28
Minerva Neurosciences
NERV
$120M
$1.98M 0.35%
+27,975
New +$1.81M
2017 Q2
0 quarters
BHVN icon
29
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.75M 0.31%
+70,000
New +$1.61M
2017 Q2
0 quarters
AGIO icon
30
Agios Pharmaceuticals
AGIO
$1.8B
$1.2M 0.21%
23,300
– –
2016 Q3
3 quarters
CCXI icon
31
DELISTED
ChemoCentryx, Inc.
CCXI
$1.1M 0.2%
118,000
– –
2017 Q1
1 quarter
BMY icon
32
Bristol-Myers Squibb
BMY
$116B
$951K 0.17%
17,060
– –
2016 Q4
2 quarters
CLVS
33
DELISTED
Clovis Oncology, Inc.
CLVS
$936K 0.17%
+10,000
New +$612K
2017 Q2
0 quarters
ALNY icon
34
Alnylam Pharmaceuticals
ALNY
$29.9B
$831K 0.15%
+10,425
New +$666K
2017 Q2
0 quarters
SGEN
35
DELISTED
Seagen Inc. Common Stock
SGEN
$776K 0.14%
+15,000
New +$953K
2017 Q2
0 quarters
PETX
36
DELISTED
Aratana Therapeutics, Inc.
PETX
$723K 0.13%
+100,000
New +$615K
2017 Q2
0 quarters
ATRA icon
37
Atara Biotherapeutics
ATRA
$93.4M
– –
-17,392
Closed -$8.94M –
SNDX icon
38
Syndax Pharmaceuticals
SNDX
$1.25B
– –
-35,301
Closed -$484K –
WVE icon
39
Wave Life Sciences
WVE
$619M
– –
-10,000
Closed -$275K –
XNCR icon
40
Xencor
XNCR
$1.75B
– –
-234,813
Closed -$5.62M –
SYRS icon
41
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-6,360
Closed -$1.01M –
ARAV
42
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-16,667
Closed -$2.13M –
JNCE
43
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-258,457
Closed -$5.68M –
VIVE
44
DELISTED
VIVEVE MED INC
VIVE
– –
-250
Closed -$1.58M –
FWP
45
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
– –
-718
Closed -$108K –
CASC
46
CALL
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-103,800
Closed -$430K –
OREX
47
DELISTED
Orexigen Therapeutics, Inc.
OREX
– –
-117,726
Closed -$405K –
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2017 Portfolio in Review

As of Q2 2017, EcoR1 Capital held 47 positions worth $563M, up 42% from $396M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

EcoR1 Capital deployed $106M of net new capital in Q2 2017, opening 15 new positions and adding to 6 existing holdings. Its largest new stake was Forte Biosciences: 4,006 shares worth $18.1M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 86% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Aclaris Therapeutics, an estimated $13.3M trimmed.

  • EcoR1 Capital's largest Q2 2017 buy was Forte Biosciences: 4,006 shares worth $18.1M.
  • EcoR1 Capital added most to Kyntra Bio in Q2 2017, an estimated $43M increase.
  • EcoR1 Capital's biggest Q2 2017 reduction was Aclaris Therapeutics, cutting an estimated $13.3M.
  • EcoR1 Capital fully exited Atara Biotherapeutics in Q2 2017, selling an estimated $8.94M.
  • EcoR1 Capital's ten largest holdings make up 79% of its $563M portfolio in Q2 2017.
  • EcoR1 Capital opened 15 new positions and closed 11 in Q2 2017.
  • EcoR1 Capital's portfolio value rose 42% quarter-over-quarter to $563M.

Based on EcoR1 Capital's 13F filing for Q2 2017, filed 14 Aug 2017.